{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:05:58Z","timestamp":1759017958961,"version":"3.44.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.annder.2019.04.024","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T03:28:22Z","timestamp":1559014102000},"page":"640-645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["N\u00e6vus \u00e9ruptifs sous anti-TNF alpha. Trois observations"],"prefix":"10.1016","volume":"146","author":[{"given":"C.","family":"Mazaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Breban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2019.04.024_bib0165","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2016.04.064","article-title":"Eruptive nevi associated with medications (ENAMs)","volume":"75","author":"Perry","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0170","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0190-9622(03)02482-4","article-title":"Eruptive melanocytic nevi in patients with renal allografts: report of 10\u00a0cases with dermoscopic findings","volume":"49","author":"Alaibac","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0175","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1002\/ibd.21618","article-title":"Eruptive benign melanocytic naevi during immunosuppressive therapy in a Crohn's disease patient","volume":"17","author":"De Boer","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.annder.2019.04.024_bib0180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/17425255.2017.1247155","article-title":"Drug-induced eruptive melanocytic nevi","volume":"13","author":"Vena","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.annder.2019.04.024_bib0185","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ad.2016.12.024","article-title":"Drug-induced eruptive melanocytic nevi","volume":"108","author":"Garc\u00eda-Montero","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.annder.2019.04.024_bib0190","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.annder.2012.12.012","article-title":"Anomalies pigmentaires induites par les traitements anticanc\u00e9reux. Premi\u00e8re partie\u00a0: les chimioth\u00e9rapies","volume":"140","author":"Sibaud","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.04.024_bib0195","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.annder.2008.04.016","article-title":"N\u00e6vus \u00e9ruptifs sous soraf\u00e9nib","volume":"135","author":"Bennani-Lahlou","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.04.024_bib0200","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archderm.144.6.820","article-title":"Sorafenib-induced eruptive melanocytic lesions","volume":"144","author":"Kong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0205","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","article-title":"Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42\u00a0patients","volume":"24","author":"Boussemart","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2019.04.024_bib0210","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2133.1978.tb02028.x","article-title":"Eruptive melanocytic naevi following severe bullous disease","volume":"99","author":"Kirby","year":"1978","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0215","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archderm.143.12.1555","article-title":"Long-term follow-up of a patient with eruptive melanocytic nevi after Stevens-Johnson syndrome","volume":"143","author":"Gelfer","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0220","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.annder.2012.03.020","article-title":"N\u00e6vus \u00e9ruptifs chez des patients atteints d\u2019\u00e9pidermolyse bulleuse h\u00e9r\u00e9ditaire","volume":"139","author":"Miquel","year":"2012","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.04.024_bib0225","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archdermatol.2008.623","article-title":"Alpha-mlanocyte-stimulating hormone-induced eruptive nevi","volume":"145","author":"Cardones","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0230","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1684\/ejd.2013.2227","article-title":"Eruptive naevi and darkening of pre-existing naevi 24h after a single mono-dose injection of melanotan II","volume":"24","author":"Schulze","year":"2014","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0235","doi-asserted-by":"crossref","first-page":"644","DOI":"10.5021\/ad.2017.29.5.644","article-title":"Eruptive melanocytic nevi without any trigger in a 5-year-old healthy girl","volume":"29","author":"Lee","year":"2017","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0240","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.arcped.2015.01.010","article-title":"Syndrome du n\u00e6vus \u00e9ruptif de l\u2019enfant \u00e0 propos d\u2019un cas","volume":"22","author":"Mazaud","year":"2015","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.annder.2019.04.024_bib0245","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1111\/jdv.14784","article-title":"Eruptive nevi under tocilizumab: first case report and data analysis","volume":"32","author":"Mansour","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.04.024_bib0250","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1365-2133.2006.07189.x","article-title":"Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biological","volume":"154","author":"Bovenschen","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0255","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00054725-200307000-00013","article-title":"Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn's disease: fallacy or coincidence?","volume":"9","author":"Katsanos","year":"2003","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.annder.2019.04.024_bib0260","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1002\/ibd.21618","article-title":"Eruptive benign melanocytic naevi during immunosuppressive therapy in a Crohn's disease patient","volume":"17","author":"de Boer","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.annder.2019.04.024_bib0265","doi-asserted-by":"crossref","first-page":"777","DOI":"10.5021\/ad.2016.28.6.777","article-title":"Eruptive benign melanocytic nevi formation following adalimumab therapy in a patient with Crohn's disease","volume":"28","author":"Moon","year":"2016","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0270","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4274\/tdd.2787","article-title":"The effects of biological agents on melanocytic nevi: a preliminary report","volume":"10","author":"Do\u011fan","year":"2016","journal-title":"Turk J Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0275","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1111\/ajd.12838","article-title":"A prospective observational study of pigmented naevi changes in psoriasis patients on biologic therapy","volume":"60","author":"Choi","year":"2019","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0280","first-page":"126","article-title":"Melanocytic nevus count and dermoscopic features do not differ in psoriatic patients undergoing biological agent versus conventional drug therapy","volume":"152","author":"Pirmit","year":"2017","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.04.024_bib0285","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.annder.2019.04.024_bib0290","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/jdv.12347","article-title":"Cutaneous melanoma in patients treated with tumour necrosis factor inhibitors: a retrospective series of 15\u00a0patients","volume":"28","author":"Chabbert","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.04.024_bib0295","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.12779","article-title":"Melanoma associated with tumour necrosis factor-\u03b1 inhibitors: a Research on Adverse Drug events And Reports (RADAR) project","volume":"170","author":"Nardone","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0300","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11\u00a0European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2019.04.024_bib0305","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/MIB.0000000000000457","article-title":"Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study","volume":"21","author":"Kopylov","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.annder.2019.04.024_bib0310","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","article-title":"Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry","volume":"77","author":"Fiorentino","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0315","first-page":"330","article-title":"Melanoma, eruptive naevi and natalizumab: causal relation or coincidence?","volume":"58","author":"Mungu\u00eda-Calzada","year":"2017","journal-title":"Dermatol"},{"key":"10.1016\/j.annder.2019.04.024_bib0160","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/jdv.12675","article-title":"An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors","volume":"29","author":"van L\u00fcmig","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819301656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819301656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:07:52Z","timestamp":1758971272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963819301656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0151963819301656"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2019.04.024","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N\u00e6vus \u00e9ruptifs sous anti-TNF alpha. Trois observations","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2019.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}